# Long-term oncological outcomes of indocyanine green fluorescence imaging-guided laparoscopic lymphadenectomy for gastric cancer: 5-year outcomes from the FUGES-012 randomized clinical trial.

<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Med</journal-id><journal-title-group><journal-title>BMC Medicine</journal-title></journal-title-group><issn pub-type="epub">1741-7015</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmcid">12382156</article-id><article-id pub-id-type="pmid">40859341</article-id>
<article-id pub-id-type="publisher-id">4334</article-id><article-id pub-id-type="doi">10.1186/s12916-025-04334-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Long-term oncological outcomes of indocyanine green fluorescence imaging-guided laparoscopic lymphadenectomy for gastric cancer: 5-year outcomes from the FUGES-012 randomized clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhong</surname><given-names>Qing</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wu</surname><given-names>Dong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Liu</surname><given-names>Zhi-yu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Shang-guan</surname><given-names>Zhi-xin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Ze-ning</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Zhi-quan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Qiu</surname><given-names>Tao-yuan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Jun-yu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Yi-ming</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Guang-tan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Yi-hui</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Ping</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Xie</surname><given-names>Jian-Wei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Jian-Xian</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zheng</surname><given-names>Chao-Hui</given-names></name><address><email>wwkzch@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Chen</surname><given-names>Qi-Yue</given-names></name><address><email>690934662@qq.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Huang</surname><given-names>Chang-Ming</given-names></name><address><email>hcmlr2002@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/055gkcy74</institution-id><institution-id institution-id-type="GRID">grid.411176.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 1758 0478</institution-id><institution>Department of Gastric Surgery, </institution><institution>Fujian Medical University Union Hospital, </institution></institution-wrap>Fuzhou, China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01mv9t934</institution-id><institution-id institution-id-type="GRID">grid.419897.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0369 313X</institution-id><institution>Key Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education, </institution></institution-wrap>Fuzhou, China </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>23</volume><elocation-id>497</elocation-id><history><date date-type="received"><day>6</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>11</day><month>8</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par7">The clinical use of indocyanine green (ICG) in laparoscopic radical gastrectomy for gastric cancer remains at an exploratory stage.</p></sec><sec><title>Methods</title><p id="Par8">Participants with resectable gastric adenocarcinoma were randomly allocated in a 1:1 ratio. The primary outcome is the number of retrieved lymph nodes (LNs) and has been reported. Herein, we report the 5-year overall survival (OS) rate, 5-year disease-free survival (DFS) rate, and related recurrence patterns.</p></sec><sec><title>Results</title><p id="Par9">Total 258 patients (ICG group, 129; non-ICG group, 129) were included in the final per-protocol analysis. The 5-year OS and DFS rate of the ICG group were superior to those of the non-ICG group (all log-rank <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). After a 5-year follow-up, the ICG group had a considerably lower cumulative recurrence rate (26/129, 20.2%) than the non-ICG group (44/129, 34.1%) (Gray&#x02019;s test <italic>P</italic>&#x02009;=&#x02009;0.011), with a risk difference of&#x02009;&#x02212;&#x02009;0.140. Stratified by recurrence types, the ICG group exhibited a notably lower cumulative incidence of locoregional recurrence in comparison to the non-ICG group (ICG vs. non-ICG: 1.6% vs. 7.8%; risk difference&#x02009;= &#x02212;&#x02009;0.062; Gray&#x02019;s test <italic>P</italic>&#x02009;=&#x02009;0.019). Dynamic analysis revealed that, in comparison to the ICG group, the non-ICG group had an earlier peak time and higher peak hazard of overall recurrence (ICG vs. non-ICG: peak time: 13.9 vs. 13.1&#x000a0;months; peak hazard: 0.0065 vs. 0.0138). Furthermore, landmark analysis indicated that the early recurrence (within 2&#x000a0;years) rate in the non-ICG group was 26.8%, which was significantly higher than the 13.1% in the ICG group (<italic>P</italic>&#x02009;=&#x02009;0.006).</p></sec><sec><title>Conclusions</title><p id="Par10">ICG-guided lymphadenectomy not only significantly improved the 5-year OS and DFS but also noticeably reduced the cumulative incidence of early recurrence. These findings support the routine use of ICG fluorescence-guided lymphadenectomy in laparoscopic radical gastrectomy.</p></sec><sec><title>Trial registration</title><p id="Par11">ClinicalTrials.gov, NCT03050879.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12916-025-04334-1.</p></sec></abstract><abstract id="Abs2" abstract-type="highlights"><title>Key points</title><sec><title>Question</title><p id="Par12">Can indocyanine green (ICG) fluorescence imaging-guided laparoscopic lymphadenectomy during laparoscopic radical gastrectomy in patients with gastric cancer improve the long-term oncological outcomes than conventional lymphadenectomy?</p></sec><sec><title>Findings</title><p id="Par13">In this randomized clinical trial, 5-year OS, DFS, and cumulative incidence of recurrence were better in the ICG group compared with the non&#x02013;ICG group.</p></sec><sec><title>Meaning</title><p id="Par14">ICG fluorescence imaging-guided lymphadenectomy not only significantly improved the 5-year OS and DFS but also noticeably reduced the recurrence hazard. The routine application of ICG fluorescence-guided lymphadenectomy is recommended for laparoscopic radical gastrectomy.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12916-025-04334-1.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Indocyanine green</kwd><kwd>Randomized controlled clinical trial</kwd><kwd>Long-term oncological efficacy</kwd><kwd>Gastric cancer</kwd><kwd>Lymphadenectomy</kwd></kwd-group><funding-group><award-group><funding-source><institution>Startup Fund for scientific research, Fujian Medical University</institution></funding-source><award-id>2024QH052</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>the Joint Funds for the Innovation of Science and Technology of Fujian Province</institution></funding-source><award-id>2018Y9041</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Construction Project of Fujian Province Medical&#x0201c;Create Double High&#x0201d;</institution></funding-source><award-id>[2021]76</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par27">Gastric cancer (GC) ranks as the fifth most prevalent cancer and the fourth leading cause of cancer-related deaths globally [<xref ref-type="bibr" rid="CR1">1</xref>]. Due to the risk of&#x000a0;regional lymph node (LN) metastasis, radical LN dissection is the predominant surgical treatment for GC. Therefore, safe and thorough lymphadenectomy is important in GC surgeries [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. </p><p id="Par28">Previous studies have shown that the greater the number of LNs removed within a designated region, the better the prognosis achieved in patients with GC [<xref ref-type="bibr" rid="CR4">4</xref>]. Thus, a thorough and effective removal of regional LNs can not only increase the retrieved and positive LNs but also contribute to a more accurate staging and determination of subsequent treatment strategies, which hold great significance in improving the prognosis of GC [<xref ref-type="bibr" rid="CR5">5</xref>]. In recent years, researchers have found that indocyanine green (ICG) fluorescence imaging can better identify LNs within the hypertrophic adipose tissue owing to its excellent tissue penetration [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>]. This allows surgeons to observe LNs more clearly, perform precise localization, and guide surgical procedures in real-time. Furthermore, several retrospective studies demonstrated that ICG can enhance the visualization of LNs during laparoscopic surgery, resulting in more retrieved LNs and a better prognosis [<xref ref-type="bibr" rid="CR9">9</xref>]. However, its safety and long-term oncological efficacy need to be supported by higher quality evidence.</p><p id="Par29">Therefore, the Fujian Medical University Union Hospital Gastric Surgery Study Group (FUGES) carried out the first prospective randomized controlled trial (FUGES-012) to assess the oncological efficacy of ICG fluorescence imaging during laparoscopic radical gastrectomy. The preliminary results confirmed an effective increase in the number of LNs and a reduction in the LN non-compliance rate [<xref ref-type="bibr" rid="CR6">6</xref>]. However, 5-year oncological outcomes are often considered important indicators for determining the applicability of new techniques in surgical oncology and serve as standard endpoints in most solid tumor clinical trials [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. Since most patients in the FUGES-012 study were staged as locally advanced GC, many of them may have experienced recurrence or death after 3&#x000a0;years, making longer-term follow-up results crucial.</p><p id="Par30">Based on at least 5&#x000a0;years of regular follow-up, we updated the 5-year oncological outcomes of the FUGES-012 trial, including the 5-year overall survival (OS), 5-year disease-free survival (DFS), and recurrence patterns, to provide high-level evidence for the routine application of ICG-guided laparoscopic lymphadenectomy for GC.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design and participants</title><p id="Par31">This phase 3 parallel, open-label, randomized clinical trial was launched at Fujian Medical University Union Hospital (FMUUH), a tertiary referral teaching hospital in China (ClinicalTrials.gov, NCT03050879). Approval for the study was granted by the Institutional Review Board of FMUUH (IRB number: 2016YF015-02), and the protocol is shown in Additional file 1: Supplemental Digital Content 1. The detailed eligibility criteria are seen in Additional file 2: eTable 1.</p></sec><sec id="Sec4"><title>Interventions</title><p id="Par32">As described in a previous study [<xref ref-type="bibr" rid="CR6">6</xref>], an endoscopic injection of ICG around the tumor was given to the patients 1&#x000a0;day prior to surgery (the details of dose and injection of ICG were seen in the Procedures part of Additional file 3: Supplemental Digital Content 2, the procedures and illustration of ICG were seen in the Additional file 4: Fig. S1). All the surgical procedures were performed by the same team. The extent of resection, either distal gastrectomy or total gastrectomy, and the performance of D2 lymphadenectomy were determined based on tumor location, following the Japanese guidelines [<xref ref-type="bibr" rid="CR13">13</xref>]. Lymph node dissection at station 10 was performed as a selective dissection [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>] when (1) the primary tumor was located in the upper-middle part of the stomach and was invading the greater curvature, (2) preoperative imaging suggested splenic lymph node enlargement, or (3) lymph nodes at station 10 emitted fluorescence signals under the NIR mode. In the ICG group, Near-infrared imaging (NOVADAQ Fluorescence Surgical System (Stryker, US)) was used to ensure a thorough examination of any remaining fluorescent LNs after lymphadenectomy. When residual LNs were detected in the dissected area, we performed complementary dissection of these LNs. Also, if fluorescent LNs were detected outside the planned dissection area (No. 10 and 14v), excessive dissection was performed beyond the scope of D2 lymphadenectomy. Each patient with advanced GC (including pathological stage II and III) was recommended to receive a 6-month adjuvant chemotherapy comprised of a fluorouracil-based regimen [<xref ref-type="bibr" rid="CR13">13</xref>]. The specific choice of chemotherapy regimen and treatment duration was decided by the treating oncologist based on their judgment and expertise.</p></sec><sec id="Sec5"><title>Outcomes measurements</title><p id="Par33">The final follow-up date was 31st August 2024. The primary outcome is the total number of retrieving LNs. In the current study, we reported the secondary outcomes including the 5-year OS, 5-year DFS, and recurrence patterns. The definition of outcomes and detailed follow-up protocol has been described previously [<xref ref-type="bibr" rid="CR6">6</xref>] (the details were seen in the Outcome measurements and follow-up part of Additional file 3: Supplemental Digital Content 2). Recurrence was detected through careful medical history and physical examination, as well as necessary imaging evaluation (CT, MR, etc.), cytology, or tissue biopsy (where feasible). The cut-off time point of the early and late recurrences was 2&#x000a0;years after surgery [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Lymph node noncompliance was defined as the absence of lymph nodes that should have been excised from more than 1 lymph node station [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>].</p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par34">The per-protocol set was used for the whole analysis. Continuous variables are presented as mean&#x02009;&#x000b1;&#x02009;standard deviation (SD), while categorical variables are presented as numbers. The <italic>t</italic>-test or <italic>&#x003c7;</italic><sup>2</sup> test was used to evaluate group differences. All tests were two-sided, and the significance level was set at <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05.</p><p id="Par35">The sample size was estimated with nQuery Advisor 7.0 (Cork, Ireland), as previously described [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. The Kaplan&#x02013;Meier (K-M) method and Cox regression were used to estimate the 5-year DFS and OS rates and explore the effects of covariates. Restricted mean survival time (RMST) was defined as the area under the K-M curve within a given time window, which can quantify the survival time [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Subgroup analyses were conducted to investigate the effects of ICG on OS and DFS in different subsets, so as to eliminate the grouping bias.</p><p id="Par36">All-cause mortality was regarded as a competing event for recurrence. For disease-specific survival (DSS), death due to other causes was treated as a competing event. The Fine-Gray method and competing-risk regression were used to calculate the cumulative incidence of recurrence and DSS in the presence of competing events [<xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR26">26</xref>]. The risk differences for recurrence and all-cause mortality were calculated using the Newcombe method. The monthly hazard rates of recurrence were estimated by a kernel&#x02013;Epanechnikov smoothing method to evaluate instantaneous conditional hazard rates [<xref ref-type="bibr" rid="CR27">27</xref>]. Landmark analysis was used to calculate the cumulative incidence of early and late recurrences [<xref ref-type="bibr" rid="CR28">28</xref>]. The clinical factors in the multi-variable analysis were selected from factors with <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 in the uni-variable analysis.</p><p id="Par37">All analyses were performed between August 2024 and December 2024 using SPSS v.25.0 for Windows (SPSS Inc. Chicago, IL, USA) or R (version 4.0.2).</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Population baseline</title><p id="Par38">From November 19, 2018, to July 13, 2019, 266 patients were randomly assigned to the ICG and non-ICG groups (133 patients in each group). Based on inclusion and exclusion criteria, the per-protocol analysis finally included 129 patients in each group (Additional file 4: Fig. S2). Baseline characteristics were basically balanced in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> (all <italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05). Compared with the non-ICG group, the number of retrieved LNs (primary outcome) was noticeably higher in the ICG group with a lower lymph node non-compliance rate (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001). The rates of receiving adjuvant chemotherapy and its regimens were similar in both groups (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05).
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline demographic and postoperative characteristics of patients in the ICG and non-ICG groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Characteristic</th><th align="left" colspan="2">No. (%)/mean (SD)</th><th align="left" rowspan="2"><italic>P</italic>-value</th></tr><tr><th align="left">Non-ICG (<italic>n</italic>=129)</th><th align="left">ICG (<italic>n</italic>=129)</th></tr></thead><tbody><tr><td align="left">Age</td><td align="left"/><td align="left"/><td align="left">0.213</td></tr><tr><td align="left">&#x02003;&#x02264;60 years</td><td align="left">58 (45.0%)</td><td align="left">68 (52.7%)</td><td align="left"/></tr><tr><td align="left">&#x02003;&#x0003e;60 years</td><td align="left">71 (55.0%)</td><td align="left">61 (47.3%)</td><td align="left"/></tr><tr><td align="left">Sex</td><td align="left"/><td align="left"/><td align="left">0.895</td></tr><tr><td align="left">&#x02003;Male</td><td align="left">87 (67.4%)</td><td align="left">86 (66.7%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Female</td><td align="left">42 (32.6%)</td><td align="left">43 (33.3%)</td><td align="left"/></tr><tr><td align="left">ECOG performance status</td><td align="left"/><td align="left"/><td align="left">0.848</td></tr><tr><td align="left">&#x02003;0</td><td align="left">113 (87.6%)</td><td align="left">114 (88.4%)</td><td align="left"/></tr><tr><td align="left">&#x02003;1</td><td align="left">16 (12.4%)</td><td align="left">15 (11.6%)</td><td align="left"/></tr><tr><td align="left">BMI, kg/m<sup>2</sup></td><td align="left"/><td align="left"/><td align="left">0.206</td></tr><tr><td align="left">&#x02003;&#x0003c;25</td><td align="left">99 (76.7%)</td><td align="left">90 (69.8%)</td><td align="left"/></tr><tr><td align="left">&#x02003;&#x02265;25</td><td align="left">30 (23.3%)</td><td align="left">39 (30.2%)</td><td align="left"/></tr><tr><td align="left">Surgical approach</td><td align="left"/><td align="left"/><td align="left">&#x0003c;0.001</td></tr><tr><td align="left">&#x02003;Distal gastrectomy</td><td align="left">43 (33.3%)</td><td align="left">71 (55.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Total gastrectomy</td><td align="left">86 (66.7%)</td><td align="left">58 (45.0%)</td><td align="left"/></tr><tr><td align="left">Tumor size, mm</td><td align="left"/><td align="left"/><td align="left">0.079</td></tr><tr><td align="left">&#x02003;&#x0003c;30</td><td align="left">50 (38.8%)</td><td align="left">64 (49.6%)</td><td align="left"/></tr><tr><td align="left">&#x02003;&#x02265;30</td><td align="left">79 (61.2%)</td><td align="left">65 (50.4%)</td><td align="left"/></tr><tr><td align="left">Histology</td><td align="left"/><td align="left"/><td align="left">0.052</td></tr><tr><td align="left">&#x02003;Differentiated</td><td align="left">90 (69.8%)</td><td align="left">75 (58.1%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Undifferentiated</td><td align="left">39 (30.2%)</td><td align="left">54 (41.9%)</td><td align="left"/></tr><tr><td align="left">Lymphovascular invasion</td><td align="left"/><td align="left"/><td align="left">0.382</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">73 (56.6%)</td><td align="left">66 (51.2%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Positive</td><td align="left">56 (43.4%)</td><td align="left">63 (48.8%)</td><td align="left"/></tr><tr><td align="left">CT</td><td align="left"/><td align="left"/><td align="left">0.831</td></tr><tr><td align="left">&#x02003;cT1</td><td align="left">29 (22.5%)</td><td align="left">35 (27.1%)</td><td align="left"/></tr><tr><td align="left">&#x02003;cT2</td><td align="left">32 (24.8%)</td><td align="left">31 (24.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;cT3</td><td align="left">38 (29.5%)</td><td align="left">37 (28.7%)</td><td align="left"/></tr><tr><td align="left">&#x02003;cT4a</td><td align="left">30 (23.3%)</td><td align="left">26 (20.2%)</td><td align="left"/></tr><tr><td align="left">CN</td><td align="left"/><td align="left"/><td align="left">0.452</td></tr><tr><td align="left">&#x02003;cN0</td><td align="left">54 (41.9%)</td><td align="left">60 (46.5%)</td><td align="left"/></tr><tr><td align="left">&#x02003;cN+</td><td align="left">75 (58.1%)</td><td align="left">69 (53.5%)</td><td align="left"/></tr><tr><td align="left">pT stage</td><td align="left"/><td align="left"/><td align="left">0.687</td></tr><tr><td align="left">&#x02003;pT1</td><td align="left">39 (30.2%)</td><td align="left">42 (32.6%)</td><td align="left"/></tr><tr><td align="left">&#x02003;pT2&#x02013;4a</td><td align="left">90 (69.8%)</td><td align="left">87 (67.4%)</td><td align="left"/></tr><tr><td align="left">pN stage</td><td align="left"/><td align="left"/><td align="left">0.900</td></tr><tr><td align="left">&#x02003;pN0</td><td align="left">55 (42.6%)</td><td align="left">54 (41.9%)</td><td align="left"/></tr><tr><td align="left">&#x02003;pN+</td><td align="left">74 (57.4%)</td><td align="left">75 (58.1%)</td><td align="left"/></tr><tr><td align="left">8th AJCC pathological stage</td><td align="left"/><td align="left"/><td align="left">0.429</td></tr><tr><td align="left">&#x02003;I</td><td align="left">41 (31.8%)</td><td align="left">50 (38.8%)</td><td align="left"/></tr><tr><td align="left">&#x02003;II</td><td align="left">33 (25.6%)</td><td align="left">33 (25.6%)</td><td align="left"/></tr><tr><td align="left">&#x02003;III</td><td align="left">55 (42.6%)</td><td align="left">46 (35.7%)</td><td align="left"/></tr><tr><td align="left">Total retrieved LNs</td><td align="left">42.0 &#x000b1; 10.3</td><td align="left">50.5 &#x000b1; 15.9</td><td align="left">&#x0003c;0.001</td></tr><tr><td align="left">LN confined to D2 lymphadenectomy</td><td align="left">41.7 &#x000b1; 10.2</td><td align="left">49.6 &#x000b1; 15.0</td><td align="left">&#x0003c;0.001</td></tr><tr><td align="left">Negative LNs</td><td align="left">36.3 &#x000b1; 12.2</td><td align="left">44.8 &#x000b1; 16.1</td><td align="left">&#x0003c;0.001</td></tr><tr><td align="left">Metastatic LNs</td><td align="left">5.7 &#x000b1; 8.9</td><td align="left">5.6 &#x000b1; 11.2</td><td align="left">0.941</td></tr><tr><td align="left">Ratio of positive lymph node</td><td align="left">0.1 &#x000b1; 0.2</td><td align="left">0.1 &#x000b1; 0.2</td><td align="left">0.383</td></tr><tr><td align="left">Lymph node Non-compliance</td><td align="left">74 (57.4%)</td><td align="left">41 (31.8%)</td><td align="left">&#x0003c;0.001</td></tr><tr><td align="left" colspan="4">Postoperative adjuvant chemotherapy</td></tr><tr><td align="left">&#x02003;Received</td><td align="left">77 (59.7%)</td><td align="left">67 (51.9%)</td><td align="left">0.210</td></tr><tr><td align="left">&#x02003;DS-1</td><td align="left">66 (85.7%)</td><td align="left">59 (88.1%)</td><td align="left"/></tr><tr><td align="left">&#x02003;SOX</td><td align="left">1 (1.3%)</td><td align="left">3 (4.5%)</td><td align="left"/></tr><tr><td align="left">&#x02003;S-1</td><td align="left">4 (5.2%)</td><td align="left">3 (4.5%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Other</td><td align="left">6 (7.8%)</td><td align="left">2 (3.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Completed</td><td align="left">51 (66.2%)</td><td align="left">49 (73.1%)</td><td align="left">0.370</td></tr><tr><td align="left">Time interval between surgery and adjuvant chemotherapy (weeks)</td><td align="left">4.7 (1.0)</td><td align="left">4.7 (1.6)</td><td align="left">0.913</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec9"><title>Surgical outcomes</title><p id="Par39">There were no significant differences between the ICG and non-ICG groups in terms of blood loss (51.5&#x000a0;mL vs 54.3&#x000a0;mL, <italic>P</italic>&#x02009;=&#x02009;0.859) and operative time (196.1&#x000a0;min vs 190.4&#x000a0;min, <italic>P</italic>&#x02009;=&#x02009;0.333; Additional file 2: eTable 2). The postoperative hospital stay was comparable between the two groups. No significant differences were found between the ICG and non-ICG groups regarding the incidence (15.5% vs. 16.3%, <italic>P</italic>&#x02009;=&#x02009;0.863) or severity of postoperative complications (3.9% vs. 4.7%, <italic>P</italic>&#x02009;=&#x02009;0.758) within 30&#x000a0;days after surgery (Additional file 2: eTable 2).</p></sec><sec id="Sec10"><title>Five-year survival outcomes</title><sec id="Sec11"><title>Overall survival</title><p id="Par40">The median duration of follow-up was 63.0&#x000a0;months. The death of 68 patients resulted in 5-year OS rates of 80.6% (25/129) in the ICG group and 66.7% (43/129) in the non-ICG group with a significant difference (log-rank <italic>P</italic>&#x02009;=&#x02009;0.018) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A). Adjusted K-M survival analysis also demonstrates the similar result (<italic>P</italic>&#x02009;=&#x02009;0.045, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>C). The cumulative incidence for all-cause death was also significantly different between the two groups (risk difference&#x02009;= &#x02212;&#x02009;0.140, HR&#x02009;=&#x02009;0.61; 95% CI, 0.37&#x02013;0.99; adjusted <italic>P</italic>&#x02009;=&#x02009;0.045) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). In addition, the 5-year RMSTs were 53.28 and 48.24&#x000a0;months in the ICG and non-ICG groups, respectively, with a difference of 5.04&#x000a0;months (Additional file 2: eTable 3). Multivariable Cox regression analysis (Additional file 2: eTable 4 and Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>) confirmed that ICG-guided lymphadenectomy was independently associated with OS (HR&#x02009;=&#x02009;0.58; 95%CI, 0.35-0.96; <italic>P</italic>&#x02009;=&#x02009;0.035). Forest plots were used to investigate the differences in 5-year OS between the two groups in different subgroups (Additional file 4: Fig. S3A&#x02013;B). The results revealed that the ICG group had superior OS than the non-ICG group among patients aged&#x02009;&#x0003e;&#x02009;60&#x000a0;years old, BMI&#x02009;&#x02265;&#x02009;25, underwent total gastrectomy, tumor size&#x02009;&#x02264;&#x02009;3&#x000a0;cm, poor differentiation, pT2-4a stage, and pN+&#x02009;stage.<fig id="Fig1"><label>Fig. 1</label><caption><p>Survival analysis of the ICG group and non-ICG group. <bold>A</bold> Comparing overall survival between the ICG group and non-ICG group. <bold>B</bold> Comparing disease-free survival between the ICG group and non-ICG group. Adjusted by tumor location, surgical approach, and pathological AJCC staging, comparing the 5-year outcomes including <bold>C</bold> overall survival <bold>D</bold> disease-free survival between the ICG group and non-ICG group</p></caption><graphic xlink:href="12916_2025_4334_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab2"><label>Table 2</label><caption><p>Frequencies of causes of first recurrence and death within 5&#x000a0;years after surgery in the ICG and non-ICG groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Events</th><th align="left" colspan="2">Surgery, No.(%)</th><th align="left" rowspan="2">Risk difference<sup>a</sup></th><th align="left" rowspan="2">Hazard ratio<break/>(95% CI)<sup>b</sup></th><th align="left" rowspan="2"><italic>P</italic> value<sup>c</sup></th><th align="left" rowspan="2">Hazard ratio<break/>(95% CI)<sup>d</sup></th><th align="left" rowspan="2">Adjusted<break/><italic>P</italic> value<sup>e</sup></th></tr><tr><th align="left">ICG group<break/>(<italic>n</italic>&#x02009;=&#x02009;129)</th><th align="left">Non-ICG group<break/>(<italic>n</italic>&#x02009;=&#x02009;129)</th></tr></thead><tbody><tr><td align="left">Any recurrence<sup>f</sup></td><td align="left">26 (20.2%)</td><td align="left">44 (34.1%)</td><td align="left">&#x02009;&#x02212;&#x02009;0.140 (&#x02212;&#x02009;0.244&#x02013;0.031)</td><td align="left">0.52 (0.31&#x02013;0.86)</td><td align="left">0.011</td><td align="left">0.56 (0.34&#x02013;0.91)</td><td align="left">0.018</td></tr><tr><td align="left">Local</td><td align="left">2 (1.6%)</td><td align="left">10 (7.8%)</td><td align="left">&#x02009;&#x02212;&#x02009;0.062 (&#x02212;&#x02009;0.122&#x02013;0.01)</td><td align="left">0.18 (0.04&#x02013;0.81)</td><td align="left">0.026</td><td align="left">0.20 (0.04&#x02013;0.92)</td><td align="left">0.038</td></tr><tr><td align="left">Peritoneal</td><td align="left">10 (7.8%)</td><td align="left">11 (8.5%)</td><td align="left">&#x02009;&#x02212;&#x02009;0.008 (&#x02212;&#x02009;0.078&#x02013;0.062)</td><td align="left">0.83 (0.35&#x02013;1.95)</td><td align="left">0.662</td><td align="left">0.85 (0.36&#x02013;2.02)</td><td align="left">0.715</td></tr><tr><td align="left">Distant</td><td align="left">14 (10.9%)</td><td align="left">23 (17.8%)</td><td align="left">&#x02009;&#x02212;&#x02009;0.07 (&#x02212;&#x02009;0.156&#x02013;0.017)</td><td align="left">0.57 (0.29&#x02013;1.10)</td><td align="left">0.095</td><td align="left">0.56 (0.29&#x02013;1.10)</td><td align="left">0.092</td></tr><tr><td align="left">&#x02003;Liver</td><td align="left">2 (1.6%)</td><td align="left">7 (5.4%)</td><td align="left">&#x02009;&#x02212;&#x02009;0.039 (&#x02212;&#x02009;0.093&#x02013;0.009)</td><td align="left">0.27 (0.06&#x02013;1.31)</td><td align="left">0.105</td><td align="left">0.26 (0.05&#x02013;1.28)</td><td align="left">0.099</td></tr><tr><td align="left">&#x02003;Multiple sites<sup>g</sup></td><td align="left">4 (3.1%)</td><td align="left">5 (3.9%)</td><td align="left">&#x02009;&#x02212;&#x02009;0.008 (&#x02212;&#x02009;0.06&#x02013;0.043)</td><td align="left">0.78 (0.21&#x02013;2.89)</td><td align="left">0.706</td><td align="left">0.88 (0.24&#x02013;3.31)</td><td align="left">0.852</td></tr><tr><td align="left">&#x02003;Other sites<sup>h</sup></td><td align="left">8 (6.2%)</td><td align="left">11 (8.5%)</td><td align="left">&#x02009;&#x02212;&#x02009;0.023 (&#x02212;&#x02009;0.091&#x02013;0.044)</td><td align="left">0.66 (0.27&#x02013;1.64)</td><td align="left">0.373</td><td align="left">0.63 (0.25&#x02013;1.58)</td><td align="left">0.324</td></tr><tr><td align="left">All-cause death<sup>i</sup></td><td align="left">25 (19.4%)</td><td align="left">43 (33.3%)</td><td align="left">&#x02009;&#x02212;&#x02009;0.140 (&#x02212;&#x02009;0.243&#x02013;0.032)</td><td align="left">0.56 (0.34&#x02013;0.91)</td><td align="left">0.020</td><td align="left">0.61 (0.37&#x02013;0.99)</td><td align="left">0.045</td></tr><tr><td align="left">Gastric cancer</td><td align="left">22 (17.8%)</td><td align="left">41 (31.8%)</td><td align="left">&#x02009;&#x02212;&#x02009;0.147 (&#x02212;&#x02009;0.248&#x02013;0.042)</td><td align="left">0.49 (0.29&#x02013;0.85)</td><td align="left">0.011</td><td align="left">0.57 (0.34&#x02013;0.95)</td><td align="left">0.032</td></tr><tr><td align="left">Other causes<sup>j</sup></td><td align="left">3 (2.3%)</td><td align="left">2 (1.6%)</td><td align="left">0.008 (&#x02212;&#x02009;0.034&#x02013;0.052)</td><td align="left">1.95 (0.29&#x02013;13.30)</td><td align="left">0.497</td><td align="left">1.28 (0.21&#x02013;7.72)</td><td align="left">0.787</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>the risk difference was calculated by the Newcombe method</p><p><sup>b</sup>For recurrence, competing-risks survival regression was used to derive the hazard ratio, 95% CI, and P value. For total recurrence, all-cause death was the competing event; for the specific types of recurrence, other types of recurrence and death were the competing events; for gastric cancer cause of death, other causes of death were the competing events, and vice versa. Univariable Cox regression was used for recurrence and all-cause death. Non-ICG group is the reference group</p><p><sup>c</sup>P value for the hazard ratios</p><p><sup>d</sup>Multivariable Cox regression was used for recurrence and all-cause death, adjustment for AJCC 8th staging, and adjuvant chemotherapy</p><p><sup>e</sup>Adjusted <italic>P</italic> value for the hazard ratios</p><p><sup>f</sup>Refers only to first-time recurrence, even though patients can have recurrence at multiple times</p><p><sup>g</sup>Includes patients who have recurrence simultaneously in 2 or more metastatic sites, including peritoneum, liver, lung, bone, brain, distant lymph node, or other hematogenous metastatic sites</p><p><sup>h</sup>Includes hematogenous recurrence at sites other than the liver (ie, lung, bone, brain, adrenal gland), recurrence at distant lymph nodes, and recurrence at uncertain sites</p><p><sup>i</sup>Post hoc exploratory outcomes. All-cause death includes death from gastric cancer and other causes</p><p><sup>j</sup>Includes other cancers, diseases other than cancer, unintentional injuries, and unknown causes</p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>Multivariable Cox regression analyses of risk factors for overall survival and disease-free survival</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Clinicopathologic parameters</th><th align="left" colspan="2">Overall survival</th><th align="left" colspan="2">Disease-free survival</th></tr><tr><th align="left">HR (95% CI)</th><th align="left"><italic>P</italic> value</th><th align="left">HR (95% CI)</th><th align="left"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="5">Group</td></tr><tr><td align="left">&#x02003;Non-ICG</td><td align="left">Ref</td><td align="left"/><td align="left">Ref</td><td align="left"/></tr><tr><td align="left">&#x02003;ICG</td><td align="left">0.58 (0.35&#x02013;0.96)</td><td align="left">0.035</td><td align="left">0.61 (0.38&#x02013;0.99)</td><td align="left">0.047</td></tr><tr><td align="left" colspan="5">Age</td></tr><tr><td align="left">&#x02003;&#x02264;60 years</td><td align="left">Ref</td><td align="left"/><td align="left">Ref</td><td align="left"/></tr><tr><td align="left">&#x02003;&#x0003e;60 years</td><td align="left">1.72 (1.01&#x02013;2.91)</td><td align="left">0.045</td><td align="left">1.41 (0.85&#x02013;2.32)</td><td align="left">0.179</td></tr><tr><td align="left" colspan="5">Surgical approach</td></tr><tr><td align="left">&#x02003;Distal gastrectomy</td><td align="left">Ref</td><td align="left"/><td align="left">Ref</td><td align="left"/></tr><tr><td align="left">&#x02003;Total gastrectomy</td><td align="left">1.65 (0.91&#x02013;2.97)</td><td align="left">0.098</td><td align="left">1.50 (0.85&#x02013;2.65)</td><td align="left">0.157</td></tr><tr><td align="left" colspan="5">Tumor size, mm</td></tr><tr><td align="left">&#x02003;&#x0003c;30</td><td align="left">Ref</td><td align="left"/><td align="left">Ref</td><td align="left"/></tr><tr><td align="left">&#x02003;&#x02265;30</td><td align="left">0.91 (0.52&#x02013;1.61)</td><td align="left">0.755</td><td align="left">1.09 (0.63&#x02013;1.91)</td><td align="left">0.755</td></tr><tr><td align="left" colspan="5">Histology</td></tr><tr><td align="left">&#x02003;Differentiated</td><td align="left">Ref</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;Undifferentiated</td><td align="left">1.84 (1.09&#x02013;3.13)</td><td align="left">0.023</td><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="5">Lymphovascular invasion</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">Ref</td><td align="left"/><td align="left">Ref</td><td align="left"/></tr><tr><td align="left">&#x02003;Positive</td><td align="left">1.08 (0.59&#x02013;1.98)</td><td align="left">0.800</td><td align="left">1.39 (0.77&#x02013;2.52)</td><td align="left">0.280</td></tr><tr><td align="left" colspan="5">8th AJCC stage</td></tr><tr><td align="left">&#x02003;I</td><td align="left">Ref</td><td align="left"/><td align="left">Ref</td><td align="left"/></tr><tr><td align="left">&#x02003;II</td><td align="left">10.79 (2.72&#x02013;42.83)</td><td align="left">0.001</td><td align="left">10.90 (2.82&#x02013;42.17)</td><td align="left">0.001</td></tr><tr><td align="left">&#x02003;III</td><td align="left">41.18 (10.67&#x02013;159.00)</td><td align="left">&#x0003c;0.001</td><td align="left">43.50 (11.45&#x02013;165.21)</td><td align="left">&#x0003c;0.001</td></tr><tr><td align="left" colspan="5">Adjuvant chemotherapy</td></tr><tr><td align="left">&#x02003;No</td><td align="left">Ref</td><td align="left"/><td align="left">Ref</td><td align="left"/></tr><tr><td align="left">&#x02003;Yes</td><td align="left">0.38 (0.20&#x02013;0.75)</td><td align="left">0.005</td><td align="left">0.36 (0.19&#x02013;0.68)</td><td align="left">0.002</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec12"><title>Disease-free survival</title><p id="Par41">The 5-year DFS rates were 77.5% and 64.3% in the ICG and non-ICG groups, respectively, with an absolute difference of 13.2% (log-rank <italic>P</italic>&#x02009;=&#x02009;0.019) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>B). Adjusted K-M survival analysis also demonstrates the similar result (<italic>P</italic>&#x02009;=&#x02009;0.032, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>D). Both Uni- and Multi-variable Cox regression analysis demonstrated that ICG-guided lymphadenectomy was an independent prognostic factor for DFS (HR&#x02009;=&#x02009;0.61; 95%CI, 0.38-0.99; <italic>P</italic>&#x02009;=&#x02009;0.047) (Additional file 2: eTable 4 and Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). Forest plots were used to investigate the differences in the 5-year DFS between the two groups in different subgroups (Additional file 4: Fig. S4A&#x02013;B). The results revealed that the ICG group had superior DFS compared to the non-ICG group among patients aged&#x02009;&#x0003e;&#x02009;60&#x000a0;years old, BMI&#x02009;&#x02265;&#x02009;25, who underwent total gastrectomy, with tumor size&#x02009;&#x02264;&#x02009;3&#x000a0;cm, poor differentiation, pT2-4a stage, and pN&#x02009;+&#x02009;stage.</p></sec></sec><sec id="Sec13"><title>Competing risk model analysis of cause of death</title><p id="Par42">In comparison to the ICG group, a higher incidence of GC-related deaths was observed in the non-ICG group (ICG vs. non-ICG: 17.8% vs. 31.8%; risk difference&#x02009;= &#x02212;&#x02009;0.147; Gray&#x02019;s test, <italic>P</italic>&#x02009;=&#x02009;0.011), whereas there were no differences in deaths due to other causes between the two groups (risk difference&#x02009;=&#x02009;0.008; Gray&#x02019;s test, <italic>P</italic>&#x02009;=&#x02009;0.600) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> and Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The competing risk regression model showed that ICG-guided lymphadenectomy was also shown to be an independent impact factor for 5-year cumulative incidence of GC-related death (sub-distribution HR&#x02009;=&#x02009;0.52, 95%CI: 0.29&#x02013;0.91, <italic>p</italic>&#x02009;=&#x02009;0.023) (Additional file 2: eTable 5).<fig id="Fig2"><label>Fig. 2</label><caption><p>Cumulative incidence of gastric cancer-related or other cause deaths between the ICG and non-ICG groups</p></caption><graphic xlink:href="12916_2025_4334_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec14"><title>Competing risk model analysis of recurrence</title><sec id="Sec15"><title>Recurrence pattern</title><p id="Par43">After a 5-year follow-up period, 26 cases of recurrence (cumulative incidence rate, 20.2%) were observed in the ICG group, while 44 cases experienced recurrence (cumulative incidence rate, 34.1%) in the non-ICG group with a risk difference of&#x02009;&#x02212;&#x02009;0.140 (Gray&#x02019;s test <italic>P</italic>&#x02009;=&#x02009;0.011) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and Additional file 4: Fig. S5A). Considering death as a competing risk factor, the competing risk regression model showed that ICG-guided lymphadenectomy was independently associated with 5-year cumulative incidence of recurrence (sub-distribution HR&#x02009;=&#x02009;0.57, 95%CI: 0.34-0.97, <italic>P</italic>&#x02009;=&#x02009;0.039) (Additional file 2: eTable 6). When stratified by pathological stages, the 5-year cumulative incidence of recurrence in the non-ICG group was significantly higher than that in the ICG group for pathological stage II-III patients; however, no significant differences were found between the ICG and non-ICG groups for pathological stage I patients (Additional file 2: eTable 7).</p><p id="Par44">Stratified by recurrence types, the 5-year cumulative incidence of local recurrence was lower in the ICG group in comparison to the non-ICG group (ICG vs. non-ICG: 1.6% vs. 7.8%; risk difference&#x02009;= &#x02212;&#x02009;0.062; Gray&#x02019;s test <italic>P</italic>&#x02009;=&#x02009;0.019). However, no significant differences were identified between the ICG and non-ICG groups in terms of the cumulative incidence of peritoneal recurrence and distant metastasis (including liver and other multi-site metastases) (all <italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05; Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and Additional file 4: Fig. S5B&#x02013;D).</p></sec><sec id="Sec16"><title>Dynamic recurrence</title><p id="Par45">Furthermore, the comparison of dynamic recurrence hazards between the ICG and non-ICG groups was presented in Additional file 4: Fig. S6. Compared to the non-ICG group, the ICG group had a lower peak hazard and delayed peak time of overall recurrence (ICG vs. non-ICG: peak time: 13.9 vs. 13.1&#x000a0;months; peak hazard: 0.0065 vs. 0.0138). In both groups, most recurrences occurred within 2&#x000a0;years, with a long hem to the right (Additional file 4: Fig. S6A). Stratified analysis showed no obvious peak time or hazard of local recurrence in the non-ICG and ICG&#x000a0;groups because of the relatively low incidence. The peak time and hazard&#x000a0;in the&#x000a0;non-ICG group were 20.8&#x000a0;months and 0.0048, respectively (Additional file 4: Fig. S6B). As for peritoneal recurrence, in comparison to the non-ICG group, a delayed peak time and lower peak hazard were observed in the ICG group (ICG vs. non-ICG: peak time: 20.9 vs. 14.3&#x000a0;months; peak hazard: 0.0025 vs. 0.0043) (Additional file 4: Fig. S6C). Similar trends were observed for distant metastases in both groups (Additional file 4: Fig. S6D).</p></sec><sec id="Sec17"><title>Early recurrence</title><p id="Par46">Landmark analysis (adjusted by pathological TNM stage and adjuvant chemotherapy) showed an early recurrence rate of 26.8% in the non-ICG group and 13.1% in the ICG group (log-rank <italic>P</italic>&#x02009;=&#x02009;0.006), while the late recurrence rates were comparable between both groups (log-rank <italic>P</italic>&#x02009;=&#x02009;0.161) (Additional file 4: Fig. S7). Multi-variate logistic regression (Additional file 2: eTable 8) showed that ICG fluorescence imaging-guided lymphadenectomy exerted an independent impact on early recurrence (OR&#x02009;=&#x02009;0.45; 95%CI, 0.21-0.97; <italic>P</italic>&#x02009;=&#x02009;0.043).</p></sec></sec></sec><sec id="Sec18"><title>Discussion</title><p id="Par47">This is the first prospective RCT worldwide to evaluate the 5-year outcomes of patients who underwent ICG-guided laparoscopic lymphadenectomy. Our study results showed that, compared with traditional laparoscopic radical gastrectomy, it can significantly improve the 5-year OS and DFS and reduce the 5-year cumulative recurrence rate, especially early recurrence. These findings provide strong evidence for the clinical application of ICG fluorescence in laparoscopic radical gastrectomy.</p><p id="Par48">Radical gastrectomy with complete LN dissection is the only potentially curative treatment for GC [<xref ref-type="bibr" rid="CR29">29</xref>]. However, due to the complex anatomical planes and vessels around the stomach and the unclear boundaries between the perigastric LNs and normal adipose tissue, it is difficult to perform thorough laparoscopic lymphadenectomy, which is technically demanding even for experienced surgeons, especially in patients with a high BMI [<xref ref-type="bibr" rid="CR30">30</xref>]. Therefore, efficient and accurate LN dissection has gradually become the focus in the surgical field of GC. With the iterative upgrade of laparoscopic imaging systems, ICG fluorescence tracing technology has attracted widespread interest for its ability to display the contours and boundaries of perigastric LNs instantaneously and further guide intraoperative LN dissection [<xref ref-type="bibr" rid="CR31">31</xref>&#x02013;<xref ref-type="bibr" rid="CR33">33</xref>], which can help surgeons perform safer and even faster lymphatic dissection by preventing unexpected injuries when dissecting lymph node&#x02013;bearing fatty tissue around blood vessels [<xref ref-type="bibr" rid="CR34">34</xref>]. Furthermore, the safety and feasibility of ICG fluorescence tracing technology have been confirmed for patients with GC in several studies and systematic reviews [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. Recently, Park et al. [<xref ref-type="bibr" rid="CR37">37</xref>] reported that better visualization of lymphatic channels, vessels, and LNs during gastric cancer surgery can encourage the surgeon to achieve the completeness of the lymphatic dissection without breakage of lymphatic structures. These detailed efforts can prevent tumor cell spillage and dissemination, ultimately resulting in improved oncological quality. This RCT also found that, compared with the non-ICG group, the ICG group exhibited a higher quality of lymphadenectomy (lower LN non-compliance rate), along with the superior OS and DFS rates. However, whether a new technology can bring sustained and stable survival benefits still needs to be supported by follow-up data over a longer period (at least 5&#x000a0;years). Currently, reports of 5-year outcomes of ICG-guided laparoscopic lymphadenectomy for GC are scarce.</p><p id="Par49">Therefore, this RCT aimed to compare the 5-year oncological outcomes between the ICG and non-ICG groups. The results showed that the 5-year OS and 5-year DFS of the ICG group were superior to those of the non-ICG group. This may be due to more retrieved LNs and a lower LN noncompliance rate [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. In standard LN dissection regions, more thorough LN dissection is not only conducive to obtaining more accurate pathological staging, allowing patients to receive more standardized postoperative adjuvant treatment and follow-up, but also reduces the residual risk of micrometastatic LNs, thereby effectively decreasing the risk of recurrence and improving the long-term survival of patients [<xref ref-type="bibr" rid="CR39">39</xref>&#x02013;<xref ref-type="bibr" rid="CR42">42</xref>]. In addition, the RMST was used to quantitatively evaluate the survival benefit of the ICG group (approximately 5&#x000a0;months), which was more intuitive and robust. As an effective supplement to traditional indicators, including the survival rate and median survival time, the RMST is helpful for understanding and decision-making in clinical practice. Through a 5-year follow-up, this study further confirmed that ICG-guided laparoscopic lymphadenectomy can achieve stable long-term oncological benefits and is expected to provide more solid and comprehensive evidence for clinical practice.</p><p id="Par50">In terms of recurrence patterns, the ICG group had a considerably lower 5-year cumulative recurrence rate compared to the non-ICG group, especially for local recurrence. ICG fluorescence tracing technology is used to visualize residual LNs within the scope of dissection to evaluate the completeness of lymphadenectomy and avoid missed dissection of micro-metastatic LNs in each region, thereby reducing the risk of local recurrence [<xref ref-type="bibr" rid="CR41">41</xref>]. However, lymphatic vessels and LNs can be traced well using high-resolution ICG fluorescence imaging, which may reduce the spread of free cancer cells caused by incorrect operative manipulations to a certain extent, thereby minimizing the risk of recurrence. Hence, this technology reflects the tumor-free principles of surgical oncology as well. In addition, dynamic risk analysis demonstrated a delayed peak time and a lower peak rate of overall recurrence in the ICG group. Landmark analysis also suggested that the early recurrence rate was noticeably lower in the ICG group. In contrast to traditional prognostic indicators, such as cumulative recurrence rate, kernel density curves can dynamically observe changes in instant hazards at different time points, which are more sensitive and detailed than conventional indicators [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. Therefore, it has been widely used in the postoperative follow-up of various cancers [<xref ref-type="bibr" rid="CR43">43</xref>&#x02013;<xref ref-type="bibr" rid="CR46">46</xref>], which can more intuitively reflect the dynamic changes in patients&#x02019; postoperative recurrence risk and is helpful for clinicians to carry out targeted intervention measures at different time points and further develop individualized follow-up strategies. This study elucidated the effect of ICG on the dynamic risk of recurrence in patients with GC through a 5-year follow-up, emphasizing the clinical value of long-term follow-up in prospective clinical trials. This study aims to provide a preliminary basis and follow-up guidance for subsequent large-scale multi-center studies (such as the CLASS-11 study) as well.</p></sec><sec id="Sec19"><title>Limitations</title><p id="Par51">This study inevitably has several limitations. Above all, this prospective clinical trial was conducted in a high-volume tertiary referral center for GC, and further validation in international multi-center studies is required. Based on the preliminary outcomes of this RCT, a nationwide RCT (CLASS-11 trial; NCT04593615) launched by the Chinese Laparoscopic Gastrointestinal Surgery Study (CLASS) group was conducted to provide further evidence. Additionally, patients who received neoadjuvant therapy were excluded to avoid any interaction effects. However, we have conducted another prospective RCT (FUGES-020 trial; NCT04611997) that specifically explored the efficacy of ICG in patients receiving neoadjuvant therapy and confirmed its safety and effectiveness in such patients [<xref ref-type="bibr" rid="CR47">47</xref>]. Finally, the protocol guideline for ICG technique was not established yet. Consistent with most previous studies [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR48">48</xref>&#x02013;<xref ref-type="bibr" rid="CR53">53</xref>], we also applied preoperative endoscopic injection of ICG around the tumor in this study, detecting enough ICG fluorescence signal rather than disappearing. Noticeably, several studies have also assessed the feasibility of intra-operative submucosal injection of ICG for real-time tracer [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. For instance, a single-arm study suggested that intra-operative endoscopic injection of ICG facilitates safe and fast infrapyloric LN dissection in laparoscopic distal gastrectomy without significantly prolonging the operation time [<xref ref-type="bibr" rid="CR34">34</xref>]. Therefore, the surgeons can choose the best injection method to alleviate economic and mental burden on patients according to their experience and hospital&#x02019;s condition. Nevertheless, this is the first RCT to confirm the long-term oncological efficacy of ICG with a 5-year follow-up, which provides a solid theoretical basis for its clinical practice.</p></sec><sec id="Sec20"><title>Conclusions</title><p id="Par52">In conclusion, for resectable GC, ICG-guided lymphadenectomy not only improves the 5-year OS and DFS but also dramatically lowers the risk of recurrence when compared to conventional lymphadenectomy. Considering its safety, feasibility, and long-term oncological benefits, ICG is recommended for routine use in patients with GC undergoing laparoscopic gastrectomy.</p></sec><sec id="Sec21" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12916_2025_4334_MOESM1_ESM.docx"><caption><p>Supplementary Material 1.&#x000a0;eTable 1. Eligibility Criteria in the FUGES-012 Study. eTable 2. Comparison of Surgical Outcomes between the ICG and non-ICG groups. eTable 3. Comparison of the Actual RMST Between the ICG and Non-ICG groups in terms of OS and DFS. eTable 4. Univariable Cox Regression Analyses of Risk Factors for Overall Survival and Disease-Free Survival. eTable 5. Univariable and Multivariable Competing Risk Analysis of Factors Associated With Risk of Disease-Specific Survival. eTable 6. Univariable and Multivariable Competing Risk Analysis of Factors Associated With Risk of Recurrence. eTable 7. Comparison of Recurrence Within 5 Years After Surgery between the ICG and Non-ICG Groups stratified by pathological stages. eTable 8. Univariable and Multivariable Logistic Regression Analysis of Factors Associated With Risk of Early Recurrence.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12916_2025_4334_MOESM2_ESM.pdf"><caption><p>Supplementary Material 2.&#x000a0;Fig.S1 Procedures Performed in ICG Group and Illustration of Fluorescent Lymph Nodes. Fig.S2 Flow chart. Fig.S3 Subgroup Analysis of the Association Between Overall Survival and ICG. (A) Univariate Analysis. (B) Multivariate Analysis was Adjusted for Age, BMI, Surgical approach, Tumor size, Histology, Pathological T stage, and N stage. Fig.S4 Subgroup Analysis of the Association between Disease-Free Survival and ICG. (A) Univariate Analysis. (B) Multivariate Analysis was Adjusted for Age, BMI, Surgical approach, Tumor size, Histology, Pathological T stage, and N stage. Fig.S5 Cumulative Incidence of Recurrence Between the ICG and Non-ICG groups. (A) Overall recurrence; (B) Local recurrence; (C) Peritoneal Recurrence; (D) Distant Metastasis. Fig.S6 Dynamic Hazard Curves for (A) Overall Recurrence and Stratifed by the (B) Local Recurrence; (C) Peritoneal Recurrence; and (D) Distant Metastasis between the ICG and Non-ICG Groups. Fig.S7 Landmark Analysis of Early and Late Recurrence Between the ICG and Non-ICG Groups.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="12916_2025_4334_MOESM3_ESM.docx"><caption><p>Supplementary Material 3.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="12916_2025_4334_MOESM4_ESM.docx"><caption><p>Supplementary Material 4.</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ICG </term><def><p id="Par15">Indocyanine green</p></def></def-item><def-item><term>LNs</term><def><p id="Par16">Lymph nodes</p></def></def-item><def-item><term>OS</term><def><p id="Par17">Overall survival</p></def></def-item><def-item><term>DFS</term><def><p id="Par18">Disease-free survival</p></def></def-item><def-item><term>GC</term><def><p id="Par19">Gastric cancer</p></def></def-item><def-item><term>FUGES</term><def><p id="Par20">Fujian Medical University Union Hospital Gastric Surgery Study Group</p></def></def-item><def-item><term>FMUUH</term><def><p id="Par21">Fujian Medical University Union Hospital</p></def></def-item><def-item><term>SD</term><def><p id="Par22">Standard deviation</p></def></def-item><def-item><term>K-M</term><def><p id="Par23">Kaplan-Meier</p></def></def-item><def-item><term>RMST</term><def><p id="Par24">Restricted mean survival time</p></def></def-item><def-item><term>DSS</term><def><p id="Par25">Disease-specific survival</p></def></def-item><def-item><term>CLASS</term><def><p id="Par26">Chinese Laparoscopic Gastrointestinal Surgery Study</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Qing Zhong, Dong Wu, Zhi-yu Liu and Zhi-xin Shang-guan contributed equally&#x000a0;to this work and should be considered co-first author.</p></fn></fn-group><ack><title>Acknowledgements
</title><p>We thank those who have devoted a lot to this study, including pathologists, further-study doctors, statisticians, and nurses. Thanks to Dr. Zhi-Hong Huang, Public Technology Service Center, Fujian Medical University. As a novel technique, we hope ICG can bring survival benefits for patients with gastric cancer.&#x000a0;This study was also&#x000a0;supported by Fujian's Overseas Study Program for Mid-Career Medical Professionals.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>Conception/Design: CMH, QYC, QZ, and DW. Collection and/or assembly of data: DW, QZ, ZYL, ZXSG, ZNH, ZQZ, TYQ, JYC, YMJ, GTL, YHT, CHZ, PL, JWX, JXL. Data analysis and interpretation: DW, QZ, ZYL, and ZXSG. Manuscript writing: DW, QZ, QYC, and CMH. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was supported by Construction Project of Fujian Province Medical &#x0201c;Create Double High&#x0201d; ([2021]76), the Joint Funds for the Innovation of Science and Technology of Fujian Province (2018Y9041), and Startup Fund for scientific research, Fujian Medical University (Grant number: 2024QH052).</p></notes><notes notes-type="data-availability"><title>Data availability
</title><p>The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par53">All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or substitute for it was obtained from all patients for being included in the study. Approval for the study was granted by the Institutional Review Board of FMUUH (IRB number: 2016YF015-02).</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par54">This article doesn&#x02019;t report an individual participant&#x02019;s data in any form.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests
</title><p id="Par55">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References
</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>H</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name><etal/></person-group><article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2021</year><volume>71</volume><issue>3</issue><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">33538338</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209&#x02013;49.<pub-id pub-id-type="pmid">33538338</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Ke</surname><given-names>B</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name></person-group><article-title>Current status of lymph node dissection in gastric cancer</article-title><source>Chin J Cancer Res</source><year>2021</year><volume>33</volume><issue>2</issue><fpage>193</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">34158739</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Ke B, Liang H. Current status of lymph node dissection in gastric cancer. Chin J Cancer Res. 2021;33(2):193&#x02013;202.<pub-id pub-id-type="pmid">34158739</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>YX</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name></person-group><article-title>Significance of nodal dissection and nodal positivity in gastric cancer</article-title><source>Transl Gastroenterol Hepatol</source><year>2020</year><volume>5</volume><fpage>17</fpage><pub-id pub-id-type="pmid">32258521</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Zhang YX, Yang K. Significance of nodal dissection and nodal positivity in gastric cancer. Transl Gastroenterol Hepatol. 2020;5:17.<pub-id pub-id-type="pmid">32258521</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Shannon</surname><given-names>AB</given-names></name><name><surname>Straker</surname><given-names>RJ</given-names></name><name><surname>Keele</surname><given-names>L</given-names></name><name><surname>Fraker</surname><given-names>DL</given-names></name><name><surname>Roses</surname><given-names>RE</given-names></name><name><surname>Miura</surname><given-names>JT</given-names></name><etal/></person-group><article-title>Lymph node evaluation after neoadjuvant chemotherapy for patients with gastric cancer</article-title><source>Ann Surg Oncol</source><year>2022</year><volume>29</volume><issue>2</issue><fpage>1242</fpage><lpage>1253</lpage><pub-id pub-id-type="pmid">34601642</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Shannon AB, Straker RJ, Keele L, Fraker DL, Roses RE, Miura JT, et al. Lymph node evaluation after neoadjuvant chemotherapy for patients with gastric cancer. Ann Surg Oncol. 2022;29(2):1242&#x02013;53.<pub-id pub-id-type="pmid">34601642</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>HJ</given-names></name><name><surname>Ahn</surname><given-names>HS</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>WH</given-names></name><name><surname>Lee</surname><given-names>KU</given-names></name><etal/></person-group><article-title>Stage migration effect on survival in gastric cancer surgery with extended lymphadenectomy: the reappraisal of positive lymph node ratio as a proper N-staging</article-title><source>Ann Surg</source><year>2012</year><volume>255</volume><issue>1</issue><fpage>50</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">21577089</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Kong SH, Lee HJ, Ahn HS, Kim JW, Kim WH, Lee KU, et al. Stage migration effect on survival in gastric cancer surgery with extended lymphadenectomy: the reappraisal of positive lymph node ratio as a proper N-staging. Ann Surg. 2012;255(1):50&#x02013;8.<pub-id pub-id-type="pmid">21577089</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>QY</given-names></name><name><surname>Xie</surname><given-names>JW</given-names></name><name><surname>Zhong</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>JB</given-names></name><name><surname>Lin</surname><given-names>JX</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Safety and efficacy of indocyanine green tracer-guided lymph node dissection during laparoscopic radical gastrectomy in patients with gastric cancer: a randomized clinical trial</article-title><source>JAMA Surg</source><year>2020</year><volume>155</volume><issue>4</issue><fpage>300</fpage><lpage>311</lpage><pub-id pub-id-type="pmid">32101269</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Chen QY, Xie JW, Zhong Q, Wang JB, Lin JX, Lu J, et al. Safety and efficacy of indocyanine green tracer-guided lymph node dissection during laparoscopic radical gastrectomy in patients with gastric cancer: a randomized clinical trial. JAMA Surg. 2020;155(4):300&#x02013;11.<pub-id pub-id-type="pmid">32101269</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>ZN</given-names></name><name><surname>Yan</surname><given-names>S</given-names></name><name><surname>Qiu</surname><given-names>WW</given-names></name><name><surname>Liu</surname><given-names>CH</given-names></name><name><surname>Chen</surname><given-names>QY</given-names></name><name><surname>Zheng</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Assessment of indocyanine green tracer-guided lymphadenectomy in laparoscopic gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: results from a multicenter analysis based on propensity matching</article-title><source>Gastric Cancer</source><year>2021</year><volume>24</volume><issue>6</issue><fpage>1355</fpage><lpage>1364</lpage><pub-id pub-id-type="pmid">34387763</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Huang ZN, Yan S, Qiu WW, Liu CH, Chen QY, Zheng CH, et al. Assessment of indocyanine green tracer-guided lymphadenectomy in laparoscopic gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: results from a multicenter analysis based on propensity matching. Gastric Cancer. 2021;24(6):1355&#x02013;64.<pub-id pub-id-type="pmid">34387763</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Senent-Boza</surname><given-names>A</given-names></name><name><surname>Garc&#x000ed;a-Fern&#x000e1;ndez</surname><given-names>N</given-names></name><name><surname>Alarc&#x000f3;n-Del Agua</surname><given-names>I</given-names></name><name><surname>Socas-Mac&#x000ed;as</surname><given-names>M</given-names></name><name><surname>de Jes&#x000fa;s-Gil</surname><given-names>&#x000c1;</given-names></name><name><surname>Morales-Conde</surname><given-names>S</given-names></name></person-group><article-title>Impact of tumor stage and neoadjuvant chemotherapy in fluorescence-guided lymphadenectomy during laparoscopic gastrectomy for gastric cancer: a propensity score-matched study in a western center</article-title><source>Surgery</source><year>2024</year><volume>175</volume><issue>2</issue><fpage>380</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">38040597</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Senent-Boza A, Garc&#x000ed;a-Fern&#x000e1;ndez N, Alarc&#x000f3;n-Del Agua I, Socas-Mac&#x000ed;as M, de Jes&#x000fa;s-Gil &#x000c1;, Morales-Conde S. Impact of tumor stage and neoadjuvant chemotherapy in fluorescence-guided lymphadenectomy during laparoscopic gastrectomy for gastric cancer: a propensity score-matched study in a western center. Surgery. 2024;175(2):380&#x02013;6.<pub-id pub-id-type="pmid">38040597</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>KY</given-names></name><name><surname>Cho</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>YM</given-names></name><name><surname>Kim</surname><given-names>HI</given-names></name><name><surname>Hyung</surname><given-names>WJ</given-names></name></person-group><article-title>Prognostic impact of fluorescent lymphography on gastric cancer</article-title><source>Int J Surg</source><year>2023</year><volume>109</volume><issue>10</issue><fpage>2926</fpage><lpage>2933</lpage><pub-id pub-id-type="pmid">37352518</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Park SH, Kim KY, Cho M, Kim YM, Kim HI, Hyung WJ. Prognostic impact of fluorescent lymphography on gastric cancer. Int J Surg. 2023;109(10):2926&#x02013;33.<pub-id pub-id-type="pmid">37352518</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Etoh</surname><given-names>T</given-names></name><name><surname>Ohyama</surname><given-names>T</given-names></name><name><surname>Sakuramoto</surname><given-names>S</given-names></name><name><surname>Tsuji</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>SW</given-names></name><name><surname>Yoshida</surname><given-names>K</given-names></name><etal/></person-group><article-title>Five-year survival outcomes of laparoscopy-assisted vs open distal gastrectomy for advanced gastric cancer: the JLSSG0901 randomized clinical trial</article-title><source>JAMA Surg</source><year>2023</year><volume>158</volume><issue>5</issue><fpage>445</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">36920382</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Etoh T, Ohyama T, Sakuramoto S, Tsuji T, Lee SW, Yoshida K, et al. Five-year survival outcomes of laparoscopy-assisted vs open distal gastrectomy for advanced gastric cancer: the JLSSG0901 randomized clinical trial. JAMA Surg. 2023;158(5):445&#x02013;54.<pub-id pub-id-type="pmid">36920382</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Son</surname><given-names>SY</given-names></name><name><surname>Hur</surname><given-names>H</given-names></name><name><surname>Hyung</surname><given-names>WJ</given-names></name><name><surname>Park</surname><given-names>YK</given-names></name><name><surname>Lee</surname><given-names>HJ</given-names></name><name><surname>An</surname><given-names>JY</given-names></name><etal/></person-group><article-title>Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer: 5-year outcomes of the KLASS-02 randomized clinical trial</article-title><source>JAMA Surg</source><year>2022</year><volume>157</volume><issue>10</issue><fpage>879</fpage><lpage>886</lpage><pub-id pub-id-type="pmid">35857305</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Son SY, Hur H, Hyung WJ, Park YK, Lee HJ, An JY, et al. Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer: 5-year outcomes of the KLASS-02 randomized clinical trial. JAMA Surg. 2022;157(10):879&#x02013;86.<pub-id pub-id-type="pmid">35857305</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Katai</surname><given-names>H</given-names></name><name><surname>Mizusawa</surname><given-names>J</given-names></name><name><surname>Katayama</surname><given-names>H</given-names></name><name><surname>Morita</surname><given-names>S</given-names></name><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Bando</surname><given-names>E</given-names></name><etal/></person-group><article-title>Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial</article-title><source>Lancet Gastroenterol Hepatol</source><year>2020</year><volume>5</volume><issue>2</issue><fpage>142</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">31757656</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Katai H, Mizusawa J, Katayama H, Morita S, Yamada T, Bando E, et al. Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial. Lancet Gastroenterol Hepatol. 2020;5(2):142&#x02013;51.<pub-id pub-id-type="pmid">31757656</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2016;20(1):1&#x02013;19.</mixed-citation></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>CM</given-names></name><name><surname>Zhang</surname><given-names>JR</given-names></name><name><surname>Zheng</surname><given-names>CH</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Xie</surname><given-names>JW</given-names></name><name><surname>Wang</surname><given-names>JB</given-names></name><etal/></person-group><article-title>A 346 case analysis for laparoscopic spleen-preserving no.10 lymph node dissection for proximal gastric cancer: a single center study</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><issue>9</issue><fpage>e108480</fpage><pub-id pub-id-type="pmid">25264673</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Huang CM, Zhang JR, Zheng CH, Li P, Xie JW, Wang JB, et al. A 346 case analysis for laparoscopic spleen-preserving no.10 lymph node dissection for proximal gastric cancer: a single center study. PLoS ONE. 2014;9(9): e108480.<pub-id pub-id-type="pmid">25264673</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>QY</given-names></name><name><surname>Huang</surname><given-names>CM</given-names></name><name><surname>Zheng</surname><given-names>CH</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Xie</surname><given-names>JW</given-names></name><name><surname>Wang</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Strategies of laparoscopic spleen-preserving splenic hilar lymph node dissection for advanced proximal gastric cancer</article-title><source>World J Gastrointest Surg</source><year>2016</year><volume>8</volume><issue>6</issue><fpage>402</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">27358672</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Chen QY, Huang CM, Zheng CH, Li P, Xie JW, Wang JB, et al. Strategies of laparoscopic spleen-preserving splenic hilar lymph node dissection for advanced proximal gastric cancer. World J Gastrointest Surg. 2016;8(6):402&#x02013;6.<pub-id pub-id-type="pmid">27358672</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Maezawa</surname><given-names>Y</given-names></name><name><surname>Aoyama</surname><given-names>T</given-names></name><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Kano</surname><given-names>K</given-names></name><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><etal/></person-group><article-title>Priority of lymph node dissection for proximal gastric cancer invading the greater curvature</article-title><source>Gastric Cancer</source><year>2018</year><volume>21</volume><issue>3</issue><fpage>569</fpage><lpage>572</lpage><pub-id pub-id-type="pmid">29119277</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Maezawa Y, Aoyama T, Yamada T, Kano K, Hayashi T, Sato T, et al. Priority of lymph node dissection for proximal gastric cancer invading the greater curvature. Gastric Cancer. 2018;21(3):569&#x02013;72.<pub-id pub-id-type="pmid">29119277</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>JF</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Oh</surname><given-names>SJ</given-names></name><name><surname>Hyung</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>Prediction of recurrence of early gastric cancer after curative resection</article-title><source>Ann Surg Oncol</source><year>2009</year><volume>16</volume><issue>7</issue><fpage>1896</fpage><lpage>1902</lpage><pub-id pub-id-type="pmid">19434457</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Lai JF, Kim S, Kim K, Li C, Oh SJ, Hyung WJ, et al. Prediction of recurrence of early gastric cancer after curative resection. Ann Surg Oncol. 2009;16(7):1896&#x02013;902.<pub-id pub-id-type="pmid">19434457</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>BB</given-names></name><name><surname>Xue</surname><given-names>Z</given-names></name><name><surname>Zheng</surname><given-names>HL</given-names></name><name><surname>Xie</surname><given-names>JW</given-names></name><etal/></person-group><article-title>A matched cohort study of the failure pattern after laparoscopic and open gastrectomy for locally advanced gastric cancer: does the operative approach matter?</article-title><source>Surg Endosc</source><year>2022</year><volume>36</volume><issue>1</issue><fpage>689</fpage><lpage>700</lpage><pub-id pub-id-type="pmid">33591445</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Lu J, Wu D, Xu BB, Xue Z, Zheng HL, Xie JW, et al. A matched cohort study of the failure pattern after laparoscopic and open gastrectomy for locally advanced gastric cancer: does the operative approach matter? Surg Endosc. 2022;36(1):689&#x02013;700.<pub-id pub-id-type="pmid">33591445</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>de Steur</surname><given-names>WO</given-names></name><name><surname>Hartgrink</surname><given-names>HH</given-names></name><name><surname>Dikken</surname><given-names>JL</given-names></name><name><surname>Putter</surname><given-names>H</given-names></name><name><surname>van de Velde</surname><given-names>CJH</given-names></name></person-group><article-title>Quality control of lymph node dissection in the Dutch gastric cancer trial</article-title><source>Br J Surg</source><year>2015</year><volume>102</volume><issue>11</issue><fpage>1388</fpage><lpage>1393</lpage><pub-id pub-id-type="pmid">26313463</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">de Steur WO, Hartgrink HH, Dikken JL, Putter H, van de Velde CJH. Quality control of lymph node dissection in the Dutch gastric cancer trial. Br J Surg. 2015;102(11):1388&#x02013;93.<pub-id pub-id-type="pmid">26313463</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>QY</given-names></name><name><surname>Lin</surname><given-names>GT</given-names></name><name><surname>Zhong</surname><given-names>Q</given-names></name><name><surname>Zheng</surname><given-names>CH</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Xie</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Laparoscopic total gastrectomy for upper-middle advanced gastric cancer: analysis based on lymph node noncompliance</article-title><source>Gastric Cancer</source><year>2020</year><volume>23</volume><issue>1</issue><fpage>184</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">31300914</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Chen QY, Lin GT, Zhong Q, Zheng CH, Li P, Xie JW, et al. Laparoscopic total gastrectomy for upper-middle advanced gastric cancer: analysis based on lymph node noncompliance. Gastric Cancer. 2020;23(1):184&#x02013;94.<pub-id pub-id-type="pmid">31300914</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Eisen</surname><given-names>T</given-names></name><name><surname>Frangou</surname><given-names>E</given-names></name><name><surname>Oza</surname><given-names>B</given-names></name><name><surname>Ritchie</surname><given-names>AWS</given-names></name><name><surname>Smith</surname><given-names>B</given-names></name><name><surname>Kaplan</surname><given-names>R</given-names></name><etal/></person-group><article-title>Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: results from the SORCE randomized phase III intergroup trial</article-title><source>J Clin Oncol</source><year>2020</year><volume>38</volume><issue>34</issue><fpage>4064</fpage><lpage>4075</lpage><pub-id pub-id-type="pmid">33052759</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Eisen T, Frangou E, Oza B, Ritchie AWS, Smith B, Kaplan R, et al. Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: results from the SORCE randomized phase III intergroup trial. J Clin Oncol. 2020;38(34):4064&#x02013;75.<pub-id pub-id-type="pmid">33052759</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>H</given-names></name><etal/></person-group><article-title>Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer: five-year outcomes from the CLASS-01 randomized clinical trial</article-title><source>JAMA Surg</source><year>2022</year><volume>157</volume><issue>1</issue><fpage>9</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">34668963</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Huang C, Liu H, Hu Y, Sun Y, Su X, Cao H, et al. Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer: five-year outcomes from the CLASS-01 randomized clinical trial. JAMA Surg. 2022;157(1):9&#x02013;17.<pub-id pub-id-type="pmid">34668963</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Beyersmann</surname><given-names>J</given-names></name><name><surname>Latouche</surname><given-names>A</given-names></name><name><surname>Buchholz</surname><given-names>A</given-names></name><name><surname>Schumacher</surname><given-names>M</given-names></name></person-group><article-title>Simulating competing risks data in survival analysis</article-title><source>Stat Med</source><year>2009</year><volume>28</volume><issue>6</issue><fpage>956</fpage><lpage>971</lpage><pub-id pub-id-type="pmid">19125387</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Beyersmann J, Latouche A, Buchholz A, Schumacher M. Simulating competing risks data in survival analysis. Stat Med. 2009;28(6):956&#x02013;71.<pub-id pub-id-type="pmid">19125387</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Fine</surname><given-names>JP</given-names></name><name><surname>Gray</surname><given-names>RJ</given-names></name></person-group><article-title>A proportional hazards model for the sub-distribution of a competing risk</article-title><source>J Am Stat Assoc</source><year>1999</year><volume>94</volume><issue>446</issue><fpage>496</fpage><lpage>509</lpage></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Fine JP, Gray RJ. A proportional hazards model for the sub-distribution of a competing risk. J Am Stat Assoc. 1999;94(446):496&#x02013;509.</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effect of laparoscopic vs open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: the CLASS-01 randomized clinical trial</article-title><source>JAMA</source><year>2019</year><volume>321</volume><issue>20</issue><fpage>1983</fpage><lpage>1992</lpage><pub-id pub-id-type="pmid">31135850</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Yu J, Huang C, Sun Y, Su X, Cao H, Hu J, et al. Effect of laparoscopic vs open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: the CLASS-01 randomized clinical trial. JAMA. 2019;321(20):1983&#x02013;92.<pub-id pub-id-type="pmid">31135850</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Schechtman</surname><given-names>E</given-names></name></person-group><article-title>Odds ratio, relative risk, absolute risk reduction, and the number needed to treat&#x02013;which of these should we use?</article-title><source>Value Health</source><year>2002</year><volume>5</volume><issue>5</issue><fpage>431</fpage><lpage>436</lpage><pub-id pub-id-type="pmid">12201860</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Schechtman E. Odds ratio, relative risk, absolute risk reduction, and the number needed to treat&#x02013;which of these should we use? Value Health. 2002;5(5):431&#x02013;6.<pub-id pub-id-type="pmid">12201860</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Hess</surname><given-names>KR</given-names></name><name><surname>Levin</surname><given-names>VA</given-names></name></person-group><article-title>Getting more out of survival data by using the hazard function</article-title><source>Clin Cancer Res</source><year>2014</year><volume>20</volume><issue>6</issue><fpage>1404</fpage><lpage>1409</lpage><pub-id pub-id-type="pmid">24501392</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Hess KR, Levin VA. Getting more out of survival data by using the hazard function. Clin Cancer Res. 2014;20(6):1404&#x02013;9.<pub-id pub-id-type="pmid">24501392</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>DeQuardo</surname><given-names>JR</given-names></name></person-group><article-title>Landmark analysis of corpus callosum shape in schizophrenia</article-title><source>Biol Psychiatry</source><year>1999</year><volume>46</volume><issue>12</issue><fpage>1712</fpage><lpage>1714</lpage><pub-id pub-id-type="pmid">10624557</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">DeQuardo JR. Landmark analysis of corpus callosum shape in schizophrenia. Biol Psychiatry. 1999;46(12):1712&#x02013;4.<pub-id pub-id-type="pmid">10624557</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Ke</surname><given-names>B</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name></person-group><article-title>Current status of lymph node dissection in gastric cancer</article-title><source>Chin J Cancer Res</source><year>2021</year><volume>33</volume><issue>2</issue><fpage>193</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">34158739</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Ke B, Liang H. Current status of lymph node dissection in gastric cancer. Chin J Cancer Res. 2021;33(2):193&#x02013;202.<pub-id pub-id-type="pmid">34158739</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Shimada</surname><given-names>S</given-names></name><name><surname>Sawada</surname><given-names>N</given-names></name><name><surname>Ishiyama</surname><given-names>Y</given-names></name><name><surname>Nakahara</surname><given-names>K</given-names></name><name><surname>Maeda</surname><given-names>C</given-names></name><name><surname>Mukai</surname><given-names>S</given-names></name><etal/></person-group><article-title>Impact of obesity on short- and long-term outcomes of laparoscopy assisted distal gastrectomy for gastric cancer</article-title><source>Surg Endosc</source><year>2018</year><volume>32</volume><issue>1</issue><fpage>358</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">28656334</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Shimada S, Sawada N, Ishiyama Y, Nakahara K, Maeda C, Mukai S, et al. Impact of obesity on short- and long-term outcomes of laparoscopy assisted distal gastrectomy for gastric cancer. Surg Endosc. 2018;32(1):358&#x02013;66.<pub-id pub-id-type="pmid">28656334</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Ishizawa</surname><given-names>T</given-names></name><name><surname>Saiura</surname><given-names>A</given-names></name></person-group><article-title>Fluorescence imaging for minimally invasive cancer surgery</article-title><source>Surg Oncol Clin N Am</source><year>2019</year><volume>28</volume><issue>1</issue><fpage>45</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">30414681</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Ishizawa T, Saiura A. Fluorescence imaging for minimally invasive cancer surgery. Surg Oncol Clin N Am. 2019;28(1):45&#x02013;60.<pub-id pub-id-type="pmid">30414681</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>IG</given-names></name><name><surname>Son</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>HI</given-names></name><name><surname>Hyung</surname><given-names>WJ</given-names></name></person-group><article-title>Fluorescent lymphography-guided lymphadenectomy during robotic radical gastrectomy for gastric cancer</article-title><source>JAMA Surg</source><year>2019</year><volume>154</volume><issue>2</issue><fpage>150</fpage><lpage>158</lpage><pub-id pub-id-type="pmid">30427990</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Kwon IG, Son T, Kim HI, Hyung WJ. Fluorescent lymphography-guided lymphadenectomy during robotic radical gastrectomy for gastric cancer. JAMA Surg. 2019;154(2):150&#x02013;8.<pub-id pub-id-type="pmid">30427990</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>QY</given-names></name><name><surname>Huang</surname><given-names>XB</given-names></name><name><surname>Lin</surname><given-names>GT</given-names></name><name><surname>Liu</surname><given-names>ZY</given-names></name><name><surname>Chen</surname><given-names>JY</given-names></name><etal/></person-group><article-title>Clinical implications of indocyanine green fluorescence imaging-guided laparoscopic lymphadenectomy for patients with gastric cancer: a cohort study from two randomized, controlled trials using individual patient data</article-title><source>Int J Surg</source><year>2021</year><volume>94</volume><fpage>106120</fpage><pub-id pub-id-type="pmid">34543741</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Zhong Q, Chen QY, Huang XB, Lin GT, Liu ZY, Chen JY, et al. Clinical implications of indocyanine green fluorescence imaging-guided laparoscopic lymphadenectomy for patients with gastric cancer: a cohort study from two randomized, controlled trials using individual patient data. Int J Surg. 2021;94: 106120.<pub-id pub-id-type="pmid">34543741</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Berlth</surname><given-names>F</given-names></name><name><surname>Choi</surname><given-names>JH</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Suh</surname><given-names>YS</given-names></name><name><surname>Kong</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Near-infrared fluorescence-guided surgery using indocyanine green facilitates secure infrapyloric lymph node dissection during laparoscopic distal gastrectomy</article-title><source>Surg Today</source><year>2020</year><volume>50</volume><issue>10</issue><fpage>1187</fpage><lpage>1196</lpage><pub-id pub-id-type="pmid">32246228</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Park SH, Berlth F, Choi JH, Park JH, Suh YS, Kong SH, et al. Near-infrared fluorescence-guided surgery using indocyanine green facilitates secure infrapyloric lymph node dissection during laparoscopic distal gastrectomy. Surg Today. 2020;50(10):1187&#x02013;96.<pub-id pub-id-type="pmid">32246228</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Dong</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Xiao</surname><given-names>K</given-names></name><name><surname>Shang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Safety and efficacy of indocyanine green fluorescence imaging-guided radical gastrectomy: a systematic review and meta-analysis</article-title><source>Expert Rev Gastroenterol Hepatol</source><year>2021</year><volume>15</volume><issue>11</issue><fpage>1319</fpage><lpage>1328</lpage><pub-id pub-id-type="pmid">34488515</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Yang J, Wang Z, Dong K, Zhang R, Xiao K, Shang L, et al. Safety and efficacy of indocyanine green fluorescence imaging-guided radical gastrectomy: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2021;15(11):1319&#x02013;28.<pub-id pub-id-type="pmid">34488515</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Puccetti</surname><given-names>F</given-names></name><name><surname>Cinelli</surname><given-names>L</given-names></name><name><surname>Genova</surname><given-names>L</given-names></name><name><surname>Battaglia</surname><given-names>S</given-names></name><name><surname>Barbieri</surname><given-names>LA</given-names></name><name><surname>Treppiedi</surname><given-names>E</given-names></name><etal/></person-group><article-title>Applicative limitations of indocyanine green fluorescence assistance to laparoscopic lymph node dissection in total gastrectomy for cancer</article-title><source>Ann Surg Oncol</source><year>2022</year><volume>29</volume><issue>9</issue><fpage>5875</fpage><lpage>5882</lpage><pub-id pub-id-type="pmid">35729291</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Puccetti F, Cinelli L, Genova L, Battaglia S, Barbieri LA, Treppiedi E, et al. Applicative limitations of indocyanine green fluorescence assistance to laparoscopic lymph node dissection in total gastrectomy for cancer. Ann Surg Oncol. 2022;29(9):5875&#x02013;82.<pub-id pub-id-type="pmid">35729291</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>JM</given-names></name><name><surname>Park</surname><given-names>SS</given-names></name></person-group><article-title>Current status and trends of minimally invasive gastrectomy in Korea</article-title><source>Medicina (Kaunas)</source><year>2021</year><volume>57</volume><issue>11</issue><fpage>1195</fpage><pub-id pub-id-type="pmid">34833413</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Park SH, Kim JM, Park SS. Current status and trends of minimally invasive gastrectomy in Korea. Medicina (Kaunas). 2021;57(11): 1195.<pub-id pub-id-type="pmid">34833413</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>QY</given-names></name><name><surname>Zhong</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>ZY</given-names></name><name><surname>Xie</surname><given-names>JW</given-names></name><name><surname>Wang</surname><given-names>JB</given-names></name><name><surname>Lin</surname><given-names>JX</given-names></name><etal/></person-group><article-title>Does noncompliance in lymph node dissection affect oncological efficacy in gastric cancer patients undergoing radical gastrectomy?</article-title><source>Ann Surg Oncol</source><year>2019</year><volume>26</volume><issue>6</issue><fpage>1759</fpage><lpage>1771</lpage><pub-id pub-id-type="pmid">30756329</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Chen QY, Zhong Q, Liu ZY, Xie JW, Wang JB, Lin JX, et al. Does noncompliance in lymph node dissection affect oncological efficacy in gastric cancer patients undergoing radical gastrectomy? Ann Surg Oncol. 2019;26(6):1759&#x02013;71.<pub-id pub-id-type="pmid">30756329</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CM</given-names></name><name><surname>Cho</surname><given-names>JM</given-names></name><name><surname>Jang</surname><given-names>YJ</given-names></name><name><surname>Park</surname><given-names>SS</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Should lymph node micrometastasis be considered in node staging for gastric cancer?: The significance of lymph node micrometastasis in gastric cancer</article-title><source>Ann Surg Oncol</source><year>2015</year><volume>22</volume><issue>3</issue><fpage>765</fpage><lpage>771</lpage><pub-id pub-id-type="pmid">25201506</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Lee CM, Cho JM, Jang YJ, Park SS, Park SH, Kim SJ, et al. Should lymph node micrometastasis be considered in node staging for gastric cancer?: The significance of lymph node micrometastasis in gastric cancer. Ann Surg Oncol. 2015;22(3):765&#x02013;71.<pub-id pub-id-type="pmid">25201506</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>SF</given-names></name><name><surname>Chen</surname><given-names>TC</given-names></name><name><surname>Hsu</surname><given-names>JT</given-names></name><name><surname>Tsai</surname><given-names>CY</given-names></name><name><surname>Liu</surname><given-names>KH</given-names></name><name><surname>Yeh</surname><given-names>CN</given-names></name><etal/></person-group><article-title>Lymph node micrometastasis of poorly differentiated node-negative gastric cancer risks a worse-than-expected survival outcome under standard management algorithm</article-title><source>Eur J Surg Oncol</source><year>2022</year><volume>48</volume><issue>4</issue><fpage>783</fpage><lpage>788</lpage><pub-id pub-id-type="pmid">34838393</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Huang SF, Chen TC, Hsu JT, Tsai CY, Liu KH, Yeh CN, et al. Lymph node micrometastasis of poorly differentiated node-negative gastric cancer risks a worse-than-expected survival outcome under standard management algorithm. Eur J Surg Oncol. 2022;48(4):783&#x02013;8.<pub-id pub-id-type="pmid">34838393</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>TH</given-names></name><name><surname>Kong</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Son</surname><given-names>YG</given-names></name><name><surname>Huh</surname><given-names>YJ</given-names></name><name><surname>Suh</surname><given-names>YS</given-names></name><etal/></person-group><article-title>Assessment of the completeness of lymph node dissection using near-infrared imaging with indocyanine green in laparoscopic gastrectomy for gastric cancer</article-title><source>J Gastric Cancer</source><year>2018</year><volume>18</volume><issue>2</issue><fpage>161</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">29984066</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Kim TH, Kong SH, Park JH, Son YG, Huh YJ, Suh YS, et al. Assessment of the completeness of lymph node dissection using near-infrared imaging with indocyanine green in laparoscopic gastrectomy for gastric cancer. J Gastric Cancer. 2018;18(2):161&#x02013;71.<pub-id pub-id-type="pmid">29984066</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Jeuck</surname><given-names>TL</given-names></name><name><surname>Wittekind</surname><given-names>C</given-names></name></person-group><article-title>Gastric carcinoma: stage migration by immunohistochemically detected lymph node micrometastases</article-title><source>Gastric Cancer</source><year>2015</year><volume>18</volume><issue>1</issue><fpage>100</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">24550066</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Jeuck TL, Wittekind C. Gastric carcinoma: stage migration by immunohistochemically detected lymph node micrometastases. Gastric Cancer. 2015;18(1):100&#x02013;8.<pub-id pub-id-type="pmid">24550066</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Xue</surname><given-names>Z</given-names></name><name><surname>Zhong</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>BB</given-names></name><name><surname>Zheng</surname><given-names>HL</given-names></name><etal/></person-group><article-title>Evaluation of dynamic recurrence risk for locally advanced gastric cancer in the clinical setting of adjuvant chemotherapy: a real-world study with IPTW-based conditional recurrence analysis</article-title><source>BMC Cancer</source><year>2023</year><volume>23</volume><issue>1</issue><fpage>964</fpage><pub-id pub-id-type="pmid">37821825</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Wu D, Lu J, Xue Z, Zhong Q, Xu BB, Zheng HL, et al. Evaluation of dynamic recurrence risk for locally advanced gastric cancer in the clinical setting of adjuvant chemotherapy: a real-world study with IPTW-based conditional recurrence analysis. BMC Cancer. 2023;23(1):964.<pub-id pub-id-type="pmid">37821825</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Kudose</surname><given-names>Y</given-names></name><name><surname>Shida</surname><given-names>D</given-names></name><name><surname>Ahiko</surname><given-names>Y</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Sakamoto</surname><given-names>R</given-names></name><name><surname>Moritani</surname><given-names>K</given-names></name><etal/></person-group><article-title>Evaluation of recurrence risk after curative resection for patients with stage I to III colorectal cancer using the hazard function: retrospective analysis of a single-institution large cohort</article-title><source>Ann Surg</source><year>2022</year><volume>275</volume><issue>4</issue><fpage>727</fpage><lpage>734</lpage><pub-id pub-id-type="pmid">32541220</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Kudose Y, Shida D, Ahiko Y, Nakamura Y, Sakamoto R, Moritani K, et al. Evaluation of recurrence risk after curative resection for patients with stage I to III colorectal cancer using the hazard function: retrospective analysis of a single-institution large cohort. Ann Surg. 2022;275(4):727&#x02013;34.<pub-id pub-id-type="pmid">32541220</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Kanematsu</surname><given-names>K</given-names></name><name><surname>Kudose</surname><given-names>Y</given-names></name><name><surname>Utsunomiya</surname><given-names>D</given-names></name><name><surname>Kubo</surname><given-names>K</given-names></name><name><surname>Fujii</surname><given-names>Y</given-names></name><name><surname>Kurita</surname><given-names>D</given-names></name><etal/></person-group><article-title>Surveillance strategy after curative resection for oesophageal squamous cell cancer using the hazard function</article-title><source>BMC Cancer</source><year>2022</year><volume>22</volume><issue>1</issue><fpage>1245</fpage><pub-id pub-id-type="pmid">36457081</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Kanematsu K, Kudose Y, Utsunomiya D, Kubo K, Fujii Y, Kurita D, et al. Surveillance strategy after curative resection for oesophageal squamous cell cancer using the hazard function. BMC Cancer. 2022;22(1):1245.<pub-id pub-id-type="pmid">36457081</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Alaimo</surname><given-names>L</given-names></name><name><surname>Moazzam</surname><given-names>Z</given-names></name><name><surname>Lima</surname><given-names>HA</given-names></name><name><surname>Endo</surname><given-names>Y</given-names></name><name><surname>Woldesenbet</surname><given-names>S</given-names></name><name><surname>Ejaz</surname><given-names>A</given-names></name><etal/></person-group><article-title>Impact of staging concordance and downstaging after neoadjuvant therapy on survival following resection of intrahepatic cholangiocarcinoma: a Bayesian analysis</article-title><source>Ann Surg Oncol</source><year>2023</year><volume>30</volume><issue>8</issue><fpage>4799</fpage><lpage>4808</lpage><pub-id pub-id-type="pmid">37029867</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Alaimo L, Moazzam Z, Lima HA, Endo Y, Woldesenbet S, Ejaz A, et al. Impact of staging concordance and downstaging after neoadjuvant therapy on survival following resection of intrahepatic cholangiocarcinoma: a Bayesian analysis. Ann Surg Oncol. 2023;30(8):4799&#x02013;808.<pub-id pub-id-type="pmid">37029867</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>ZN</given-names></name><name><surname>Tang</surname><given-names>YH</given-names></name><name><surname>Zhong</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Xie</surname><given-names>JW</given-names></name><name><surname>Wang</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Assessment of laparoscopic indocyanine green tracer-guided lymphadenectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: a randomized controlled trial</article-title><source>Ann Surg</source><year>2024</year><volume>279</volume><issue>6</issue><fpage>923</fpage><lpage>931</lpage><pub-id pub-id-type="pmid">38375670</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Huang ZN, Tang YH, Zhong Q, Li P, Xie JW, Wang JB, et al. Assessment of laparoscopic indocyanine green tracer-guided lymphadenectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: a randomized controlled trial. Ann Surg. 2024;279(6):923&#x02013;31.<pub-id pub-id-type="pmid">38375670</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Cianchi</surname><given-names>F</given-names></name><name><surname>Indennitate</surname><given-names>G</given-names></name><name><surname>Paoli</surname><given-names>B</given-names></name><name><surname>Ortolani</surname><given-names>M</given-names></name><name><surname>Lami</surname><given-names>G</given-names></name><name><surname>Manetti</surname><given-names>N</given-names></name><etal/></person-group><article-title>The clinical value of fluorescent lymphography with indocyanine green during robotic surgery for gastric cancer: a matched cohort study</article-title><source>J Gastrointest Surg</source><year>2020</year><volume>24</volume><fpage>2197</fpage><lpage>2203</lpage><pub-id pub-id-type="pmid">31485904</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Cianchi F, Indennitate G, Paoli B, Ortolani M, Lami G, Manetti N, et al. The clinical value of fluorescent lymphography with indocyanine green during robotic surgery for gastric cancer: a matched cohort study. J Gastrointest Surg. 2020;24:2197&#x02013;203.<pub-id pub-id-type="pmid">31485904</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>MK</given-names></name><name><surname>Cho</surname><given-names>M</given-names></name><name><surname>Roh</surname><given-names>CK</given-names></name><name><surname>Seo</surname><given-names>WJ</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name><name><surname>Son</surname><given-names>T</given-names></name><etal/></person-group><article-title>Assessment of diagnostic value of fluorescent lymphography-guided lymphadenectomy for gastric cancer</article-title><source>Gastric Cancer</source><year>2021</year><volume>24</volume><fpage>515</fpage><lpage>525</lpage><pub-id pub-id-type="pmid">32945996</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Jung MK, Cho M, Roh CK, Seo WJ, Choi S, Son T, et al. Assessment of diagnostic value of fluorescent lymphography-guided lymphadenectomy for gastric cancer. Gastric Cancer. 2021;24:515&#x02013;25.<pub-id pub-id-type="pmid">32945996</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>JH</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name><name><surname>Cho</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>YM</given-names></name><name><surname>Kim</surname><given-names>HI</given-names></name><etal/></person-group><article-title>Fluorescent lymphography during minimally invasive total gastrectomy for gastric cancer: an effective technique for splenic hilar lymph node dissection</article-title><source>Surg Endosc</source><year>2022</year><volume>36</volume><fpage>2914</fpage><lpage>2924</lpage><pub-id pub-id-type="pmid">34109482</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Lee S, Song JH, Choi S, Cho M, Kim YM, Kim HI, et al. Fluorescent lymphography during minimally invasive total gastrectomy for gastric cancer: an effective technique for splenic hilar lymph node dissection. Surg Endosc. 2022;36:2914&#x02013;24.<pub-id pub-id-type="pmid">34109482</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>L</given-names></name><etal/></person-group><article-title>Safety and efficacy of carbon nanoparticle suspension injection and indocyanine green tracer-guided lymph node dissection during robotic distal gastrectomy in patients with gastric cancer</article-title><source>Surg Endosc</source><year>2022</year><volume>36</volume><fpage>3209</fpage><lpage>3216</lpage><pub-id pub-id-type="pmid">34254184</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Tian Y, Lin Y, Guo H, Hu Y, Li Y, Fan L, et al. Safety and efficacy of carbon nanoparticle suspension injection and indocyanine green tracer-guided lymph node dissection during robotic distal gastrectomy in patients with gastric cancer. Surg Endosc. 2022;36:3209&#x02013;16.<pub-id pub-id-type="pmid">34254184</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>BW</given-names></name><name><surname>Lee</surname><given-names>WY</given-names></name></person-group><article-title>The oncologic safety and accuracy of indocyanine green fluorescent dye marking in securing the proximal resection margin during totally laparoscopic distal gastrectomy for gastric cancer: a retrospective comparative study</article-title><source>World J Surg Oncol</source><year>2022</year><volume>20</volume><fpage>26</fpage><pub-id pub-id-type="pmid">35090476</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Yoon BW, Lee WY. The oncologic safety and accuracy of indocyanine green fluorescent dye marking in securing the proximal resection margin during totally laparoscopic distal gastrectomy for gastric cancer: a retrospective comparative study. World J Surg Oncol. 2022;20:26.<pub-id pub-id-type="pmid">35090476</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Sposito</surname><given-names>C</given-names></name><name><surname>Maspero</surname><given-names>M</given-names></name><name><surname>Conalbi</surname><given-names>V</given-names></name><name><surname>Magarotto</surname><given-names>A</given-names></name><name><surname>Altomare</surname><given-names>M</given-names></name><name><surname>Battiston</surname><given-names>C</given-names></name><etal/></person-group><article-title>Impact of indocyanine green fluorescence imaging on lymphadenectomy quality during laparoscopic distal gastrectomy for gastric cancer (Greeneye): an adaptative, phase 2, clinical trial</article-title><source>Ann Surg Oncol</source><year>2023</year><volume>30</volume><fpage>6803</fpage><lpage>6811</lpage><pub-id pub-id-type="pmid">37442913</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Sposito C, Maspero M, Conalbi V, Magarotto A, Altomare M, Battiston C, et al. Impact of indocyanine green fluorescence imaging on lymphadenectomy quality during laparoscopic distal gastrectomy for gastric cancer (Greeneye): an adaptative, phase 2, clinical trial. Ann Surg Oncol. 2023;30:6803&#x02013;11.<pub-id pub-id-type="pmid">37442913</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>SH</given-names></name><name><surname>Noh</surname><given-names>YW</given-names></name><name><surname>Suh</surname><given-names>YS</given-names></name><name><surname>Park</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>HJ</given-names></name><name><surname>Kang</surname><given-names>KW</given-names></name><etal/></person-group><article-title>Evaluation of the novel near-infrared fluorescence tracers pullulan polymer nanogel and indocyanine green/&#x003b3;-glutamic acid complex for sentinel lymph node navigation surgery in large animal models</article-title><source>Gastric Cancer</source><year>2015</year><volume>18</volume><issue>1</issue><fpage>55</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">24481855</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Kong SH, Noh YW, Suh YS, Park HS, Lee HJ, Kang KW, et al. Evaluation of the novel near-infrared fluorescence tracers pullulan polymer nanogel and indocyanine green/&#x003b3;-glutamic acid complex for sentinel lymph node navigation surgery in large animal models. Gastric Cancer. 2015;18(1):55&#x02013;64.<pub-id pub-id-type="pmid">24481855</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>